Edgewise Therapeutics (EWTX) Stock Analysis

What Edgewise Therapeutics does

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Key metrics

ETFs linked to EWTX

Broad-market and Healthcare sector ETFs an investor holding Edgewise Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EWTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Edgewise Therapeutics?

Edgewise Therapeutics trades under the ticker EWTX on NASDAQ.

Which exchange is EWTX listed on?

EWTX is listed on NASDAQ.

What sector does Edgewise Therapeutics operate in?

Edgewise Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EWTX in a portfolio?

PortView shows EWTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.